These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 25832874)
1. Pazopanib for the treatment of renal cell carcinoma. Welsh SJ; Fife K Future Oncol; 2015; 11(8):1169-79. PubMed ID: 25832874 [TBL] [Abstract][Full Text] [Related]
2. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas]. Brotelle T; Bay JO Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453 [TBL] [Abstract][Full Text] [Related]
3. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Choueiri TK; Fay AP; Gagnon R; Lin Y; Bahamon B; Brown V; Rosenberg JE; Hutson TE; Baker-Neblett KL; Carpenter C; Liu Y; Pandite L; Signoretti S Clin Cancer Res; 2013 Sep; 19(18):5218-26. PubMed ID: 23881929 [TBL] [Abstract][Full Text] [Related]
4. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience. Topal A; Sayın S; Gokyer A; Kucukarda A; Kostek O; Bekir Hacıoglu M; Uzunoglu S; Erdogan B; Cicin I J BUON; 2021; 26(4):1628-1634. PubMed ID: 34565028 [TBL] [Abstract][Full Text] [Related]
5. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial. Xie M; He CS; Huang JK; Lin QZ Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828 [TBL] [Abstract][Full Text] [Related]
6. Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. Rinchai D; Verzoni E; Huber V; Cova A; Squarcina P; De Cecco L; de Braud F; Ratta R; Dugo M; Lalli L; Vallacchi V; Rodolfo M; Roelands J; Castelli C; Chaussabel D; Procopio G; Bedognetti D; Rivoltini L Clin Transl Med; 2021 Jun; 11(6):e434. PubMed ID: 34185403 [TBL] [Abstract][Full Text] [Related]
7. Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database. Hackshaw MD; Nagar SP; Parks DC; Miller LA J Manag Care Spec Pharm; 2014 Jun; 20(6):603-10. PubMed ID: 24856598 [TBL] [Abstract][Full Text] [Related]
8. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial. Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823 [TBL] [Abstract][Full Text] [Related]
9. Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study). Sepe P; Martinetti A; Mennitto A; Verzoni E; Claps M; Raimondi A; Sottotetti E; Grassi P; Guadalupi V; Stellato M; Zattarin E; Di Maio M; Procopio G Am J Clin Oncol; 2020 Sep; 43(9):621-627. PubMed ID: 32889831 [TBL] [Abstract][Full Text] [Related]
10. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma. McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220 [TBL] [Abstract][Full Text] [Related]
11. Pazopanib for the treatment of renal cancer. Al-Marrawi MY; Rini B Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066 [TBL] [Abstract][Full Text] [Related]
12. Pazopanib for the treatment of metastatic renal cell carcinoma. Pick AM; Nystrom KK Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567 [TBL] [Abstract][Full Text] [Related]
13. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma. Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943 [TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma. Zivi A; Cerbone L; Recine F; Sternberg CN Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374 [TBL] [Abstract][Full Text] [Related]
15. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience. Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089 [TBL] [Abstract][Full Text] [Related]
16. A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma. Kim MJ; Park SH; Lee JL; Lee SH; Lee SJ; Lim HY BMC Urol; 2016 Aug; 16(1):46. PubMed ID: 27484998 [TBL] [Abstract][Full Text] [Related]
17. Vanishing bile duct syndrome associated with pazopanib after progression on pembrolizumab. Zhong YY; McLean L; Buckle A; Siva S; Tran B Can J Urol; 2020 Aug; 27(4):10339-10341. PubMed ID: 32861263 [TBL] [Abstract][Full Text] [Related]
18. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Keisner SV; Shah SR Drugs; 2011 Mar; 71(4):443-54. PubMed ID: 21395357 [TBL] [Abstract][Full Text] [Related]
19. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma. Bianconi M; Faloppi L; Loretelli C; Zizzi A; Giampieri R; Bittoni A; Andrikou K; Del Prete M; Burattini L; Montironi R; Scartozzi M; Cascinu S Oncotarget; 2016 Jun; 7(25):37599-37607. PubMed ID: 27175586 [TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma. Haaland B; Chopra A; Acharyya S; Fay AP; Lopes Gde L BMC Cancer; 2014 Aug; 14():592. PubMed ID: 25127891 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]